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bstract
Different liquisolid formulations of carbamazepine were accomplished by dissolving the drug in the non-toxic hydrophilic liquids, and adsorb-
ng the solution onto the surface of silica. In order to reduce the amounts of carrier and aerosil in liquisolid formulations, some additives namely
olyvinylpyrrolidone (PVP), hydroxypropyle methylcellulose (HPMC) and polyethylene glycol (PEG 35000) were added to liquid medication to
ncrease loading factor. The effects of various ratios of carrier to coating material, PVP concentration, effect of aging and type of the carrier on
issolution rate of liquisolid compacts were studied. X-ray crystallography and differential scanning calorimetery (DSC) were used for evalua-
ion of physicochemical properties of carbamazepine in liquisolid formulations. The results showed that the drug loading factor was increased
ignificantly in the presence of additives. Liquisolid formulations containing PVP as additive, exhibited significantly higher drug dissolution
ates compared to the compacts prepared by the direct compression technique. It was shown that microcrystalline cellulose had more liquid
etention potential in comparison with lactose, and the formulations containing microcrystalline cellulose as carrier, showed higher dissolution
ate. By decreasing the ratio of microcrystalline cellulose to silica from 20 to 10, an improvement in dissolution rate was observed. Further
ecrease in the ratio of microcrystalline cellulose:silica from 10 to 5 resulted in a significant reduction in dissolution rate. Increasing of PVP
oncentration in liquid medication caused a dramatic increase in dissolution rate at first 30 min. The results showed that the dissolution rate of
iquisolid tablets was not significantly affected by storing the tablets at 25 ◦C/75% relative humidity for a period of 6 months. The results of DSC
nd X-ray crystallography did not show any changes in crystallinity of the drug and interaction between carbamazepine and exipients during
he process.
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. Introduction
It is well established that the active ingredient in a solid
osage form must undergo dissolution before it is available for
bsorption from the gastrointestinal tract. The poor dissolution
haracteristics of water-insoluble drugs are a major challenge
or pharmaceutical scientists. The absorption rate of a poorly
ater-soluble drug, formulated as an orally administered solid
osage form, is controlled by its dissolution rate in the fluid
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resent at the absorption site, i.e. the dissolution rate is often
he rate-determining step in drug absorption. There are several
ethods for enhancing dissolution rate of poorly water-soluble
rugs including: (a) reducing particle size to increase surface
rea, thus increasing dissolution rate of drug; (b) solubilization
n surfactant systems; (c) formation of water-soluble complexes;
d) drug derivatization such as a strong electrolyte salt forms
hat usually have higher dissolution rate and (e) manipulation
f solid state of drug substance to improve drug dissolution,
.e. by decreasing crystallinity of drug substance through for-ation of solid solutions (Kapsi and Ayres, 2001). The most
ommon method is to increase surface area of the drug by
icronization. But, in practice the effect of micronization is
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r tableted (Aguiar et al., 1979; Finholt and Solvang, 1968;
in et al., 1968). Micronised drugs also have the tendency to
gglomerate as a result of their hydrophobicity, thus reducing
heir available surface area (Finholt and Solvang, 1968). Sev-
ral researchers have shown that the liquisolid technique is the
ost promising method for promoting dissolution rate of poorly
ater-soluble drugs (Javadzadeh et al., 2005; Nokhodchi et al.,
005b; Spireas and Sadu, 1998; Spireas et al., 1998, 1999). A
liquisolid system” refers to formulations formed by conversion
f liquid drugs (such as vitamin A, clofibrtae), drug suspensions
r drug solution in non-volatile solvents into dry, nonadherent,
ree-flowing and compressible powder mixtures by blending the
uspension or solution with selected carriers and coating mate-
ials (Spireas and Sadu, 1998). This technique was successfully
pplied for low dose water-insoluble drugs. However, formu-
ation of the high dose insoluble-drugs as liquisolid tablets is
ne of the limitations of the liquisolid technique. In order to
ave acceptable flowability and compactability for liquisolid
owder formulation, high levels of carrier and coating materials
hould be added and that in turn will increase the weight of each
ablet above 1 g which is very difficult to swallow. Therefore,
n practice it is impossible with conventional method to con-
ert high dose drugs to liquisolid tablet with the tablet weight
f less than 1 g. In fact, when the therapeutic dose of drug is
ore than 50 mg, dissolution enhancement in the presence of
ow levels of hydrophilic carrier and coating material is not
ignificant. We believe that by adding some materials such as
olyvinyl pyrrolidone (PVP) to liquid medication (microsys-
ems), it would be possible to produce dry powder formulations
ontaining liquid with high concentration of drug. By adding
uch materials to the liquid medication, low amount of carrier
s required to obtain dry powder with free flowability and good
ompactibility.
Carbamazepine (CBZ), 5H-dibenzazepine-5-carboxamide,
s a sodium channel blocker that has been in routine use in the
reatment of epilepsy and trigeminal neuralgia for over 40 years
Martindale, 1999). This agent belongs to class II drugs that
ts bioavailability is limited by its poor dissolution rate in GI.
n fact, its solubility and dissolution rate are key factors in its
ioavailability. In this study, carbamazepine was chosen as a
odel drug to examine capability of microsytems for obtaining
iquisolid tablets with enhanced dissolution rate for drugs that
ave therapeutic dose more than 50 mg.
. Materials and methods
.1. Materials
Carbamazepine was provided by Sobhan Co. (Rasht, Iran).
oarse granular microcrystalline cellulose (Mingtai Chemical,
aiwan), sodium starch glycolate (Yung Zip Chemical, Tai-
an), nm-sized amorphous silicon dioxide (Mingtai Chemical),
olysorbate 80 (Merck, Germany), PEG 400 (Merck, Germany),
lycerin (Merck, Germany), PEG 200 (Merck, Germany), PG
Merck, Germany), PVP K25 (BASF, Germany), HPMC K4M
Colorcon, England), lactose, starch, sorbitol and sodium chlo-
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.2. Solubility studies
To select the best non-volatile solvent for dissolving or
uspending of carbamazepine in liquid medication, solubility
tudies of carbamazepine were carried out in five different non-
olatile solvents, i.e. PEG 200, PEG 400, glycerin, polysorbate
0 and PG. Saturated solutions were prepared by adding excess
rug to the vehicles and shaking on the shaker (Velp, Italy) for
8 h at 25 ◦C under constant vibration. After this period the solu-
ions were filtered through a 0.45m Millipore filter, diluted
ith distilled water containing sodium lauryl sulphate (SLS)
nd analysed by UV-spectrophotometer (Shimadzu, Japan) at
wavelength of 284.4 nm against blank sample (blank sample
ontained the same concentration of specific solvent used with-
ut drug). Three determinations were carried out for each sample
o calculate the solubility of carbamazepine.
.3. Calculation of the loading factor (Lf)
To calculate the loading factor, different concentrations (w/w)
f polymers (PVP, HPMC K4M and PEG 35000) were dissolved
n the PEG 200 (carbamazepine showed the highest solubility
n PEG 200). Each of the above system (liquid medication with-
ut drug) was added to 30 g of microcrystalline cellulose–silica
owder mixture or lactose as a carrier material and blended for
0 min. By using Lf =W/Q formula (W: amount of liquid med-
cation and Q: amount of carrier material), the drug loading
actors were obtained and used for calculating the amount of
arrier and coating materials in each formulation. The prelimi-
ary results showed that if the viscosity of the carrier was higher,
ower amounts of microcrystalline cellulose powder are needed
o produce flowable powder. The low viscosity grade of HPMC
HPMC LV100) was tried, but an appropriate powder flow was
ot achievable.
.4. Flow properties of liquisolid powders
Two techniques were used to evaluate the flow properties of
owders: hopper flow rate and angle of repose. In hopper flow
ate technique, 100 cm3 of powders was placed in the funnel of
owmeter (Erweka, Germany). A simple shutter is placed over
he hopper outlet (the orifice size was 6 mm) and the hopper
lled with powder. The shutter is then removed and the time
aken for the powder to discharge completely is recorded. By
ividing the discharge powder volume by this time, a flow rate
s obtained which can be used for quantitative comparison of
ifferent powders. The flow rate above 10 cm3/s was considered
s acceptable flow rate for tableting purpose in this research.
Flow properties of the powders were also evaluated by deter-
ining the angle of repose. Static angle of repose was measured
ccording to the fixed funnel and freestanding cone method. A
unnel with the end of the stem cut perpendicular to the axis of
ymmetry is secured with its tip 10 cm height, H, above a graph
aper placed on a flat horizontal surface. The powders were care-
ully poured through the funnel until the apex of the conical pile
o formed just reaches the tip of the funnel. The mean diameter,
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angent of the angle of repose was given by:
an α = H
R
here α is the repose angle.
.5. Preparation of conventional tablet and liquisolid
ompacts
Carbamazepine conventional tablets were produced by
ixing the drug with microcrystalline cellulose–silica (with
ifferent ratios of microcrystalline cellulose to silica) and the
dditive for a period of 10 min in a cubic mixer (Erweka, Type
G, Germany). The mixture was mixed with sodium starch gly-
olate (5%, w/w, of the formulation) for 10 min. The mixture
as compressed on a 10-mm punch and die using a manual-
ableting machine (Riken, Japan). Sufficient compression load
as applied in order to produce tablets with the hardness of
6–70 N (Newton). This formulation was denoted as direct
ompression tablet (DCT) and each tablet contains 100 mg car-
amazepine, 400 mg microcrystalline cellulose or lactose as
carrier material, 20 mg nm-sized silica as coating material
26.67 mg in formulations with ratio of 15:1 of carrier to coating
aterial) and 25 mg sodium starch glycolate (as a disintegrating
gent).
Several liquisolid compacts, denoted as LS-1 to LS-18
Table 1) were prepared as follows. Carbamazepine was dis-
ersed in PEG 200 (PEG 200 was used as the liquid vehicle to
repare the liquid medication). Then various polymers namely
VP, HPMC and PEG 35000 were dissolved in PEG 200 con-
aining carbamazepine. Then a binary mixture of carrier-coating
aterials (microcrystalline cellulose or lactose, as the carrier
owder and silica as the coating material) was added to the
btained liquid medication under continuous mixing in a mortar.





ey formulation characteristics of prepared formulations
ormulation Additive in liquid medication Carrier Ratio of ca
S-1 PVP MCCa 20
S-2 HPMC MCC 20
S-3 PEG35000 MCC 20
S-4 PVP MCC 15
S-5 HPMC MCC 15
S-6 PEG35000 MCC 15
S-7 PVP Lactose 20
S-8 HPMC Lactose 20
S-9 PEG35000 Lactose 20
S-10 PVP Lactose 15
S-11 HPMC Lactose 15
S-12 PEG35000 Lactose 15
S-13 PVP MCC 20
S-14 HPMC MCC 20
S-15 PEG35000 MCC 20
S-16 PVP Lactose 15
S-17 HPMC Lactose 15
S-18 PEG35000 Lactose 15
n all formulations, the concentration of drug in liquid medication was 50% and addi
a MCC is microcrystalline cellulose.of Pharmaceutics 341 (2007) 26–34
id loading factors were employed in our liquisolid preparations.
inally, 5% (w/w) of sodium starch glycolate as the disintegrant,
as mixed with the mixture for a period of 10 min. The final
ixture was compressed using the manual tableting machine
o achieve tablet hardness of 56–70 N. Important formulation
haracteristics of the prepared carbamazepine liquisolid formu-
ations are shown in Table 1.
.6. Dissolution studies
The USP paddle method (Erweka, DPT6R, Germany) was
sed for all the in vitro dissolution studies. In this method, dis-
illed water containing 1% (w/v) sodium lauryl sulphate without
nzyme, was used as dissolution media. The rate of stirring
as 100 ± 2 rpm. The amount of carbamazepine was 100 mg
n all formulations. The dosage forms were placed in 900 ml
f distilled water containing 1% (w/v) SLS and maintained at
7 ± 0.1 ◦C. At appropriate intervals (5, 10, 15, 20, 30, 45,
0 and 90 min), 5 ml of the samples were taken and filtered
hrough a 0.45m Millipore filter. The dissolution media was
hen replaced by 5 ml of fresh dissolution fluid to maintain a
onstant volume. After proper dilution, the samples were then
nalysed at 284.4 by UV/vis spectrophotometer. The mean of
ix determinations was used to calculate the drug release from
ach of the formulations.
The in vitro release profiles of liquisolid tablets and con-
entional tablets were compared using similarity factors, f2, as
efined by the following equation (Costa, 2001).












here n is number of time points at which %dissolved was deter-
ined,Rt the %dissolved of one formulation at a given time point
nd Tt is the %dissolved of the formulation to be compared at



































































Q5 min (%) T50% (min)
LS-1 23.8 17 24 ± 1 18 ± 2
LS-2 11.1 27 14 ± 2 28 ± 2
LS-3 18.9 19 10 ± 1 21 ± 1
DCT1 18.5 18 17 ± 1 30 ± 2
LS-4 26.3 16 30 ± 2 14 ± 2
LS-5 13.5 23 19 ± 2 20 ± 2
LS-6 19.6 19 12 ± 1 19 ± 2
DCT2 20.1 16 14 ± 2 26 ± 3
LS-7 11.4 26 14 ± 2 21 ± 2
LS-8 10.3 29 14 ± 2 43 ± 3
LS-9 11.2 27 10 ± 2 24 ± 4
DCT3 30.4 25 18 ± 1 21 ± 3
LS-10 13.5 22 17 ± 5 22 ± 3
LS-11 11.2 27 18 ± 1 42 ± 5
LS-12 11.5 25 17 ± 1 20 ± 2
DCT4 26.0 16 17 ± 1 20 ± 2
LS-13 23.8 16 20 ± 1 25 ± 1
LS-14 11.1 25 12 ± 1 41 ± 2
LS-15 18.9 21 28 ± 2 15 ± 2
Powder mix 18.5 18 15 ± 1 41 ± 4
LS-16 13.5 24 29 ± 1 20 ± 2













after the release of 90% was excluded from the graphs (but not
from the experiments). It is clear from Fig. 1 the formulations
containing PVP as additive (LS-1) has a better dissolution rate in
comparison with conventional direct compressed tablet (DCT),Y. Javadzadeh et al. / International Jo
he same time point. The similarity factor fits the result between
and 100. It is 100 when the test and reference profiles are
dentical and approaches 0 as the dissimilarity increases. An f2
bove 50 indicates that the two profiles are similar.
.7. X-ray powder diffraction
X-ray diffractometery of drug, excipient and formulations
ere done using Siemens diffractometer (Siemens, D5000-
ermany). The cross section of samples was exposed to X-ray
adiation (Cu K) with wavelength of 1.5406 ◦A. The rate of the
canning was 0.6◦/min. Samples, ground into powders with an
gate mortar and pestle, were measured on a low background
uartz plate in an aluminum holder.
.8. Differential scanning calorimetry (DSC)
Thermograms of the samples (carbamazepine, exipients and
iquisolid formulations) were recorded on a DSC-60 (Shimadzu,
apan). Samples (3–5 mg weighed to a precision of 0.005 mg)
ere placed in aluminum pans and the lids were crimped using
Shimadzu crimper. Thermal behavior of the samples was
nvestigated under at scanning rate of 20 ◦C/min, covering a tem-
erature range of 30–200 ◦C. The instrument was calibrated with
n indium standard.
.9. Statistical analysis
All the data were statistically analysed by analysis of vari-
nce or Tukey’s multiple comparison test. Results are quoted as
ignificant where p< 0.05.
. Results and discussion
.1. Solubility and dissolution studies
The solubility of carbamazepine in PG, PEG 400, PEG 200,
lycerin and polysorbate 80 is given in Table 2. The table shows
hat the solubility of carbamazepine in PEG 200 is higher in
omparison with other solvents. In fact, the higher fraction of
rug in PEG 200 is in the molecular state in comparison with
thers solvents and this would help to increase dissolution rate of
he drug because some percentages of drug is already dissolved.
It has been shown that in conventional liquisolid tablets, it is
ifficult to prepare formulation with good flowability and com-
actibility when loading factor is above 0.25 (Javadzadeh et al.,
able 2
olubility of carbamazepine in various solvents (n= 3)
olvent Solubility (mg/ml)
ropylene glycol 40.896 ± 0.525
EG 400 71.820 ± 0.722
EG 200 87.668 ± 1.101
lycerin 7.789 ± 0.156
olysorbate 80 45.831 ± 0.575 F
lS-18 11.5 26 34 ± 2 14 ± 1
owder mix 26.0 16 13 ± 2 32 ± 2
005; Nokhodchi et al., 2005a,b). We believe that by preparing
icrosystems (adding some additives such as PVP, HPMC or
EG 35000 into liquid medication), the loading factor can be
ncreased above 0.25. The results showed that the loading factor
or the samples containing PEG 35000 was 0.6 (Table 1) and still
hese formulations possess good flow properties (Table 3). The
issolution profiles of liquisolid formulations containing differ-
nt types of additives are shown in Fig. 1. In all cases, 100% of
issolution occurred between 3 and 4 h. However, for a better
omparison of the results using the graphs dissolution profilesig. 1. Effect of various additives on dissolution profile of carbamazepine from
iquisolid tablets (ratio of microcrystalline cellulose to silica is 20:1).
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ormulations containing HPMC (LS-2) and PEG 35000 (LS-3)
s additives. Liquisolid tablets containing PEG 35000 had the
owest dissolution rate within the first 5 min. In order to have a
etter comparison, Q5 min (percent drug dissolved within 5 min)
nd T50% (time required for the dissolution of 50% drug) were
alculated (Table 3). Comparing Q5 min for these formulations
evealed that liquisolid tablets containing PEG35000 (LS-3)
ere the slow release formulations (Table 3). This is due to the
igher disintegration time of these tablets (14 min). When the
isintegration of tablet was completed the dissolution rate was
ncreased in comparison with DC tablet (compare T50% values in
able 3). PEG 35000 is a waxy-like material and wetting of tablet
y dissolution media is difficult. In other words, PEG 35000
ight increase the viscosity of the stagnant diffusion layer and
ecrease dissolution rate of the drug and these can describe that
hy LS-3 had a lower dissolution rate in comparison with LS-
tablet. Sample containing HPMC showed fast disintegration
less than 1 min) due to swelling behavior of HPMC. However,
he low dissolution rate of LS-2 in comparison with LS-1 is due
o gel forming properties of HPMC around the disintegrated par-
icles. The high viscosity around drug particles may slow down
he penetration of water into particles and this in turn will reduce
he dissolution rate of drug from particles. The main reason for
he increased dissolution of the drug in presence of PVP might
e due to crystal growth inhibition. It has been shown that PVP
ay serve to inhibit precipitation of drug from the supersaturated
olution (Simonelli et al., 1976; Usui et al., 1997). Another rea-
on for the increased dissolution of drug in presence of PVP
ould be the increased surface area of the drug exposed to the
issolution medium as a result of the adsorption on carrier.
Similar results were obtained when ratio of microcrystalline
ellulose to silica was altered from 20:1 to 15:1 (Fig. 2).
iquisolid compacts containing PVP with different ratios of
icrocrystalline cellulose:silica showed different dissolutionates. For example when the ratio of microcrystalline cellu-
ose:silica was changed from 20:1 to 15:1, the dissolution rate of
arbamazepine increased (compare LS-1 with LS-4). As silica
as high surface area (200 m2/g), then higher amounts of drug
ig. 2. Effect of various additives on dissolution profile of carbamazepine from






















Tig. 3. Dissolution profiles of liquisolid tablets containing lactose (ratio of
actose:silica is 20:1).
n molecular state (dissolved in PEG 200) could be adsorbed
n its surface. This status will expose more drugs to the disso-
ution media, and then higher dissolution rate of drug could be
btained.
To evaluate the effect of type of carrier on dissolution profile,
everal formulations were prepared using lactose as carrier and
issolution test were performed. As it is clear from Fig. 3, there is
o significant difference between DCT tablet and liquisolid for-
ulations containing PVP (LS-7), PEG 35000 (LS-9) as additive
n liquid medication (similarity factor, f2 >50 also see T50% in
able 3). Microcrystalline cellulose has disintegration property,
hich could facilitate disintegration of tablets and dissolution
f drug. Because of the presence of a nonvolatile solvent acting
s a binding agent in the liquisolid formulation, delayed disin-
egration time is expected. However, in the liquisolid tablets
ontaining microcrystalline cellulose, a fast disintegration of
ablet (less than 1 min) occurred which can be explained by
he disintegrating property of microcrystalline cellulose with an
xception of the tablets containing PEG 35000 (disintegration
ime was 16 min). All liquisolid tablets containing lactose as
he carrier showed disintegration time above 13 min. Fig. 3 also
howed that the LS-8 formulation containing HPMC as additive
ad a low dissolution rate. This could be due to the formation of
el around the disintegrated particles by HPMC, which builds
barrier against diffusion of the dissolved drug into dissolution
edium. Similar results were obtained in 15:1 ratio of lactose
o silica (Fig. 4).
As mentioned, the delayed disintegration time of tablets (for
xample, tablets containing PEG 35000 as additive or lactose
s carrier material) could be the main reason for the lower dis-
olution rate of these formulations. To evaluate the hypothesis,
issolution test was carried out for the formulated liquisolid
owders (without converting them into tablets, LS-13 up to LS-
8). The results were summarized in Figs. 5 and 6. There were
o significant differences between the conventional formulation
nd liquisolid powders containing HPMC (p> 0.05). In contrast
o the liquisolid tablets, the liquisolid powder containing PEG
5000 showed higher dissolution rate among the formulations.
his shows that the delayed disintegration could be a reason for
Y. Javadzadeh et al. / International Journal of Pharmaceutics 341 (2007) 26–34 31
Fig. 4. Dissolution profile of liquisolid tablets containing lactose as carrier (ratio





























oig. 5. Dissolution profiles of liquisolid powders containing microcrystalline
ellulose as carrier.
ower dissolution rate of PEG liquisolid tablet especially within
rst 15 min. Comparing the dissolution rate of liquisolid pow-
ers containing microcrystalline cellulose (Fig. 5) and lactose
Fig. 6), showed no significant difference between their disso-
ution profiles indicating that the difference observed between



















tig. 7. Effect of various ratio of carrier to coating material (microcrystalline
ellulose:silica) on dissolution profile of carbamazepine liquisolid tablets con-
aining PVP as an additive.
he tablets made from these two formulations (see Figs. 1–6) is
ue to the disintegration property of microcrystalline cellulose
compare Q5 min and T50% of these formulations in Table 3). For
xample, Q5 min values for LS-15 (liquisolid powder contain-
ng microcrystalline cellulose) and LS-18 (liquisolid containing
actose) were 14 and 15 min, respectively.
Fig. 7 shows the effect of various ratios of microcrystalline
ellulose to silica. As it is clear from this figure, a reduction
n the ratio of microcrystalline cellulose to silica from 20:1
o 10:1 showed a slight increase in the dissolution of carba-
azepine within first 30 min, but when this ratio was reduced to
, a lower dissolution rate was observed. Liquisolid compacts
ith lower R-values contain relatively smaller amounts of car-
ier powder (cellulose), and larger quantities of fine drug loaded
ilica particles, and the ratios of the amounts of their liquid med-
cation per powder substrate are relatively higher. On the other
and, liquisolid compacts with higher R-values contain low liq-
id/powder ratios, high presence of cellulose and low presence
f silica. This could be directly associated with enhanced wick-
ng, disintegration and deaggregation properties. Therefore, the
iquisolid tablets with low R-values showed relatively poor dis-
olution (Fig. 7). In addition, during the dissolution process,
he primary particles produced after the disintegration of the
iquisolid tablets with low R-values are overloaded with liq-
id medication. In such cases, even though the drug diffusion
hrough the primary particles may be rapid, it might lead to
verwhelming (solubility-wise) of the stagnant (adjacent to the
rimary particles) dissolution layers with drug, resulting in local
recipitation of carbamazepine during the initial stages of the
issolution process, thereby presenting decreased dissolution
ates (Spireas et al., 1999).
In order to study the effect of aging on hardness and disso-
ution profile of carbamazepine liquisolid compacts, six tablets
rom LS-4 series were kept at 25 ◦C/75% relative humidity for 6
onths. Then hardness and dissolution rate were measured forhese tablets. The results showed that there was no significant
ifference between the hardness of fresh (62.3 ± 7 N) and aged
59.5 ± 7.7 N) liquisolid tablets (p> 0.05). This indicated that
he hardness of liquisolid compacts was not affected by aging.









































carbamazepine and pure exipients, physical mixture (car-
bamazepine, lactose, microcrystalline cellulose, PVP and
silica) and liquisolid formulation. Carbamazepine diffractogramig. 8. Effect of aging on dissolution profile of carbamazepine liquisolid tablets.
Fig. 8 shows the dissolution profile of fresh and aged
iquisolid tablets. Although the aged liquisolid tablets appear
o have lower dissolution rate than fresh liquisolid tablets in the
raph, similarity factor of the two release profiles was 57.7, indi-
ating acceptably similar profiles. This means that aging has no
ffect on dissolution behavior of the carbamazepine liquisolid
ompacts. However, when Q5 min and T50% were compared for
reshly made liquisolid compacts and aged liquisolid compacts
y t-test opposite results were obtained. However, still the aged
iquisolid compacts have higher dissolution rate than the con-
entional tablets.
To assess the PVP effect on the dissolution rate, various for-
ulations with different concentrations of PVP were prepared
nd dissolution tests were carried out (ratio of microcrystalline
ellulose:silica was 15:1 in all these formulations). According
o Fig. 9, the formulation containing 30% of PVP, had better
issolution rate within first 30 min, but after 30 min, there was
o significant differences (p> 0.05) between percentages dis-
olved for carbamazepine liquisolid tablets containing different
oncentrations of PVP.
ig. 9. Effect of various concentrations of PVP in liquid medication on disso-
ution profile of carbamazepine liquisolid tablets.
F
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.2. Solid state characterization of carbamazepine in
iquisolid formulations
The drug might precipitate after adsorption of the drug solu-
ion onto the adsorbent. The potential precipitation is dependent
n the solubility of the drug in the solvent and the degree of
aturation of the drug solution or interaction between compo-
ents. It has been shown that polymorphic changes of the drug
re important factors that may affect the dissolution rate and
ioavailability (Abdou, 1989). Therefore, it is important to study
he polymorphic changes of carbamazepine in liquisolid formu-
ations. Carbamazepine has been found to crystallize as four
ifferent anhydrous polymorphs (Himes et al., 1981; Lowes
t al., 1987; Ceolin et al., 1997; Nokhodchi et al., 2005a;
olourtchian et al., 2001). The most reliable way to distinguish
etween the four polymorphs of CBZ is with PXRD. Form I has
iagnostic peaks at 2θ = 7.92, 9.37, 12.28 and 19.99. Form II is
ecognizable because it has few high intensity peaks at 2θ = 8.68,
3.26, 18.56 and 24.54. The indicative peaks for form III occur
t 2θ = 15.36, 19.56, 25.00 and 27.47. Form IV has characteristic
eaks at 2θ = 14.11, 17.89, 21.79 and 33.11.
Fig. 10 shows the X-ray diffractograms of the pureig. 10. X-ray diffractograms of pure carbamazepine, PVP, lactose, microcrys-
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howed sharp peaks, 2θ at 15.36, 19.56, 25 and 27.47. This corre-
ponds to form III polymorph of carbamazepine (Grzesiak et al.,
003). As it is clear from Fig. 10, liquisolid and physical mixture
ormulations have the same diffraction patterns. It can be con-
luded that no alterations in crystallinity of carbamazepine or
nteraction between drug and exipients occurred during the for-
ulation process. Diffractograms of other formulations showed
he same results.
One useful technique to study of polymorphism is differen-
ial scanning calorimetry (DSC). DSC is usually combined with
RPD to determine the polymorphic composition of pharma-
eutical powders, when the polymorphs present have different
elting points. DSC thermograms of carbamazepine polymorph
orm I show no transformation and melts between 189 and
93 ◦C (Himes et al., 1981). Form II does not melt, but instead
transformation occurs between 135 and 170 ◦C and the new
hase then melts between 188 and 192 ◦C. The large transfor-
ation range is due, in part, to higher initiation temperatures for
rystals with fewer defects as determined by observing popula-
ions of crystals during heating. Form III melts and crystallizes to
new form nearly simultaneously between 162 and 175 ◦C. The
ew form subsequently melts between 189 and 193 ◦C. Form IV
hows melting and partial crystallization to a new form between
78 and 187 ◦C, significantly higher than the transition tempera-
ures of forms II or III. This is followed by further crystallization
o produce a material that then melts between 190 and 192 ◦C.
ased on the melting point of the form that is derived from the
ig. 11. Differential scanning calorimetery of silica, lactose, carbamazepine,
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thers upon heating, it appeared that each had become form I
Himes et al., 1981).
The results of DSC thermograms confirmed the above conclu-
ion (Fig. 11). According to the Fig. 11, carbamazepine showed
n endothermic peak around its melting point. The liquisolid
nd physical mixture formulations showed the same peaks in
his area, which indicates that there is no interaction between
rug and exipients or changes in crystallinity of the drug during
he formulation process. From above finding it can be concluded
hat the enhanced dissolution rate of carbamazepine liquisolid
ompacts is not due to the formation of complex between the
rug and exipients or changes in crystallinity of the drug. It has
lready been shown that wetting of the tablets and drug parti-
le had important impact on dissolution of poorly water-soluble
rugs (Javadzadeh et al., 2007). We believe that, therefore, in the
resent study due to significantly improved wetting properties
f liquisolid compacts and drug particles, liquisolid compacts
isplay enhanced drug dissolution characteristics.
. Conclusion
This study provided evidence that it is possible to load high
mounts of drug into liquisolid tablets by addition of PVP to
he liquid medication. This is valuable for the preparation of
iquisolid tablets of high dose drugs. The liquisolid tablets pre-
ared with PVP showed a remarkably improved dissolution
ate in comparison with DC tablet and other formulations. The
esults showed that dissolution rate of the drug from liquisolid
ompacts or powders was affected by changing the ratio of the
arrier (microcrystalline cellulose or lactose) to coating mate-
ial (aerosil). Further, microcrystalline cellulose was a better
arrier than was lactose in preparation of high dissolution rate
iquisolid tablets. Increasing the amount of PVP also resulted
n higher dissolution rate. Aging had no effect on hardness and
issolution profile of liquisolid tablets; no crystallinity changes
r interaction was observed during the process.
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